within Pharmacolibrary.Drugs.ATC.C;

model C08GA01
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.45,
    Cl             = 9.666666666666667e-06,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00062,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.025,
    Tlag           = 600,            
    Vdp             = 0.0013,
    k12             = 1.6,
    k21             = 1.6
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C08GA01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>This combination consists of nifedipine, a dihydropyridine calcium channel blocker that causes vasodilation and is mainly used for treating hypertension and angina, together with a diuretic (thiazide or thiazide-like), used to lower blood pressure by promoting renal excretion of sodium and water. The combination is approved for the treatment of hypertension and is currently in clinical use.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adults with hypertension treated with oral nifedipine in combination with diuretics, as direct published models or combination PK data with diuretics are unavailable. PK parameters are based on established PK data for nifedipine monotherapy, assuming no substantial PK drug-drug interaction with most thiazide diuretics.</p><h4>References</h4><ol><li><p>Johnson, CE, et al., &amp; Amidon, GL (1991). Pharmacokinetics and pharmacodynamics of nifedipine in children with bronchopulmonary dysplasia and pulmonary hypertension. <i>Pediatric research</i> 29(5) 500–503. DOI:<a href=\"https://doi.org/10.1203/00006450-199105010-00017\">10.1203/00006450-199105010-00017</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1896255/\">https://pubmed.ncbi.nlm.nih.gov/1896255</a></p></li><li><p>Ali, MA, et al., &amp; Itai, S (2017). Enhancing the Solubility and Oral Bioavailability of Poorly Water-Soluble Drugs Using Monoolein Cubosomes. <i>Chemical &amp; pharmaceutical bulletin</i> 65(1) 42–48. DOI:<a href=\"https://doi.org/10.1248/cpb.c16-00513\">10.1248/cpb.c16-00513</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28049915/\">https://pubmed.ncbi.nlm.nih.gov/28049915</a></p></li><li><p>McClellan, KJ, &amp; Jarvis, B (2000). Lercanidipine: a review of its use in hypertension. <i>Drugs</i> 60(5) 1123–1140. DOI:<a href=\"https://doi.org/10.2165/00003495-200060050-00009\">10.2165/00003495-200060050-00009</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11129125/\">https://pubmed.ncbi.nlm.nih.gov/11129125</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C08GA01;
